Peficitinib
| Peficitinib | |
|---|---|
| Peficitinib.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Peficitinib is a Janus kinase inhibitor (JAK inhibitor) used in the treatment of rheumatoid arthritis. It is an orally administered medication that works by inhibiting the activity of Janus kinase enzymes, which play a key role in the inflammatory process associated with rheumatoid arthritis.
Mechanism of Action[edit]
Peficitinib functions by selectively inhibiting the activity of Janus kinase enzymes, particularly JAK1 and JAK3. These enzymes are involved in the signaling pathways of various cytokines and growth factors that are crucial for the immune response and inflammation. By blocking these pathways, peficitinib reduces the inflammatory response and alleviates the symptoms of rheumatoid arthritis.
Clinical Use[edit]
Peficitinib is primarily used for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to or are intolerant to other disease-modifying antirheumatic drugs (DMARDs). It is administered orally, providing a convenient option for patients compared to injectable therapies.
Side Effects[edit]
Common side effects of peficitinib include upper respiratory tract infections, headache, and increased liver enzymes. Serious side effects may include infections, gastrointestinal perforations, and hematologic abnormalities such as anemia and neutropenia. Patients on peficitinib require regular monitoring for these potential adverse effects.
Development and Approval[edit]
Peficitinib was developed by Astellas Pharma and has been approved for use in several countries for the treatment of rheumatoid arthritis. Its development involved extensive clinical trials to establish its efficacy and safety profile.
